Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Invested Capital (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Invested Capital for 11 consecutive years, with $18.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 146.84% to $18.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.4 million, a 146.84% increase, with the full-year FY2024 number at $18.6 million, up 32.06% from a year prior.
  • Invested Capital was $18.4 million for Q3 2025 at Marker Therapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $72.5 million in Q1 2021 to a low of $7.4 million in Q3 2024.
  • A 5-year average of $26.8 million and a median of $18.6 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 55.43% in 2023, then soared 146.84% in 2025.
  • Marker Therapeutics' Invested Capital stood at $44.0 million in 2021, then plummeted by 49.75% to $22.1 million in 2022, then crashed by 36.42% to $14.1 million in 2023, then soared by 32.06% to $18.6 million in 2024, then fell by 0.91% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Invested Capital are $18.4 million (Q3 2025), $10.5 million (Q2 2025), and $14.5 million (Q1 2025).